Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Bafrekalant is a diazabicyclo-substituted imidazo[1,2-a]pyrimidine derivative that can be used to study sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 243.00 | |
5 mg | In stock | $ 597.00 | |
10 mg | In stock | $ 868.00 | |
25 mg | In stock | $ 1,290.00 | |
50 mg | In stock | $ 1,770.00 | |
100 mg | In stock | $ 2,390.00 | |
500 mg | In stock | $ 4,790.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 675.00 |
Description | Bafrekalant is a diazabicyclo-substituted imidazo[1,2-a]pyrimidine derivative that can be used to study sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring. |
Molecular Weight | 531.05 |
Formula | C29H31ClN6O2 |
CAS No. | 2256770-44-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 225.0 mg/mL (423.7 mM ), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Bafrekalant 2256770-44-0 Others inhibitor inhibit